Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00157677
Status:
COMPLETED
Last Update Posted:
2011-10-27
First Post:
2005-09-08
Brief Title:
Selective D-Dimer Testing Compared With Uniform D-Dimer Testing in the Diagnosis of Deep Vein Thrombosis SELECT
Sponsor:
McMaster University
Organization:
McMaster University
Study Overview
Official Title:
Selective D-Dimer Testing Compared With Uniform D-Dimer Testing in the Diagnosis of Deep Vein Thrombosis A Randomized Trial
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SELECT
Brief Summary:
The purpose of this study is to compare two diagnostic interventions to improve the way D-dimer blood testing MDA D-dimer is used to diagnose first time symptomatic deep vein thrombosis
Detailed Description:
Limiting use of D-dimer testing to outpatients with a Low or Moderate clinical pretest probability C-PTPfor deep vein thrombosis AND using a D-dimer level of 10 µg FEUmL to exclude deep vein thrombosis in those with a Low C-PTP and a D-dimer level of 05 µg FEUmL to exclude deep vein thrombosis in those with a Moderate C-PTP is as safe and a more efficient way to diagnose DVT than
Performing D-dimer testing in all patients with suspected deep vein thrombosis with use of a single D-dimer value of 05 µg FEUmL to exclude thrombosis current practice
All randomized patients including those who are treated for deep vein thrombosis after initial testing will be followed for a period of 3 months to monitor for signs and symptoms suggestive of deep vein thrombosis pulmonary embolism bleeds and death
Performing D-dimer testing in all patients with suspected deep vein thrombosis with use of a single D-dimer value of 05 µg FEUmL to exclude thrombosis current practice
All randomized patients including those who are treated for deep vein thrombosis after initial testing will be followed for a period of 3 months to monitor for signs and symptoms suggestive of deep vein thrombosis pulmonary embolism bleeds and death
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Grant Number NA 5429 | None | None | None |